Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 1 patents
30 readers on Mendeley
  • Article usage
  • Citations to this article (250)

Advertisement

Research Article Free access | 10.1172/JCI115485

Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells.

A J Marcus, L B Safier, K A Hajjar, H L Ullman, N Islam, M J Broekman, and A M Eiroa

Department of Medicine, Department of Veterans Affairs Medical Center, New York, NY 10010.

Find articles by Marcus, A. in: PubMed | Google Scholar

Department of Medicine, Department of Veterans Affairs Medical Center, New York, NY 10010.

Find articles by Safier, L. in: PubMed | Google Scholar

Department of Medicine, Department of Veterans Affairs Medical Center, New York, NY 10010.

Find articles by Hajjar, K. in: PubMed | Google Scholar

Department of Medicine, Department of Veterans Affairs Medical Center, New York, NY 10010.

Find articles by Ullman, H. in: PubMed | Google Scholar

Department of Medicine, Department of Veterans Affairs Medical Center, New York, NY 10010.

Find articles by Islam, N. in: PubMed | Google Scholar

Department of Medicine, Department of Veterans Affairs Medical Center, New York, NY 10010.

Find articles by Broekman, M. in: PubMed | Google Scholar

Department of Medicine, Department of Veterans Affairs Medical Center, New York, NY 10010.

Find articles by Eiroa, A. in: PubMed | Google Scholar

Published November 1, 1991 - More info

Published in Volume 88, Issue 5 on November 1, 1991
J Clin Invest. 1991;88(5):1690–1696. https://doi.org/10.1172/JCI115485.
© 1991 The American Society for Clinical Investigation
Published November 1, 1991 - Version history
View PDF
Abstract

We previously reported that platelets become unresponsive to agonists when stimulated in combined suspension with aspirin-treated human umbilical vein endothelial cells. Inhibition occurred concomitant with metabolism of platelet-derived endoperoxides to prostacyclin by endothelial cells. We now demonstrate that if aspirin-treated platelets which fully respond to appropriate doses of agonists are exposed to aspirin-treated endothelial cells, they remain unresponsive despite absence of prostacyclin. Platelet inhibition is due in large part to ecto-ADPase activity on the endothelial cells. This was established by incubating aspirin-treated endothelial cells with 14C-ADP. Radio-thin layer chromatography and aggregometry demonstrated that 14C-ADP and induction of platelet activation decreased rapidly and concurrently. AMP accumulated transiently, was further metabolized to adenosine, and deaminated to inosine. The apparent Km of the endothelial cell ADPase was 33-42 microM and the Vmax 17-43 nmol/min per 10(6) cells, values in the range of antithrombotic potential. Thus, at least three complementary systems in human endothelial cells control platelet responsiveness: a cell-associated, aspirin-insensitive ADPase which functions in parallel with fluid phase autacoids such as the aspirin-inhibitable eicosanoids, and the aspirin-insensitive endothelium-derived relaxing factor.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1690
page 1690
icon of scanned page 1691
page 1691
icon of scanned page 1692
page 1692
icon of scanned page 1693
page 1693
icon of scanned page 1694
page 1694
icon of scanned page 1695
page 1695
icon of scanned page 1696
page 1696
Version history
  • Version 1 (November 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (250)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
30 readers on Mendeley
See more details